Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health ...

The Lancet obesity framework aims to improve risk assessment but risks delaying treatment and deepening health inequities, according to recent evaluations.

Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...

The Endocrine Society has concerns of possible delays in care and other problematic areas of The Lancet Commission’s proposed new obesity framework; a Commission author cites ‘conceptual confusions.’ ...

Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health problems may complicate diagnosis and delay treatment, according to an Endocrine ...

Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health ...

Medications like GLP-1 agonists, as well as minimally invasive bariatric surgeries, offer lasting results with few complications. At the same time, healthy eating and regular physical activity remain ...

News and commentary from the endocrinology world ...

The FDA approved a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related ...

The American Heart Association’s new heart diet guidelines stress early lifestyle changes to prevent heart disease. Key advice includes cutting sugar, avoiding alcohol, limiting processed foods, and ...

Many researchers prefer the “live” data that comes from real-world results while still acknowledging potential shortcomings.

Researchers have found in a new study that Tirzepatide is more effective than conventional care for improving glycemic control and overall metabolic health in early type 2 diabetes.Tirzepatide ...